logo-loader

MGC Pharmaceuticals appoints new company secretary

Published: 21:27 29 Nov 2020 EST

MGC Pharmaceuticals Ltd -
MGC Pharma creates premium phytocannabinoid-based products from its GMP facility in Europe.

MGC Pharmaceuticals Ltd (ASX:MXC) (OTCMKTS:MGCLF) (FRA:H5O) has appointed Narelle Warren as joint company secretary effective from today.

The current company secretary, Rachel Kerr is taking maternity leave starting from today.

Warren has more than 20 years of corporate advisory, financial management and company secretarial experience with emphasis on small to mid-cap listed companies in the resources, energy and biotech sectors.

Corporate experience

She has co-ordinated and assisted in numerous corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets.

Warren is qualified as a Chartered Accountant and holds a Bachelor of Laws and Bachelor of Commerce and is also the company secretary of ASX-listed Invex Therapeutics Ltd (ASX:IXC).

Drawdown of convertible notes

MGC Pharma is completing a drawdown under a convertible securities financing agreement with US-based investment fund Mercer Street Global Opportunity Fund LLC.

The drawdown will provide the company with funding of A$3.5 million, which has already been approved by shareholders at the Annual General Meeting on November 4.  

This will be provided through the issue of 3.85 million convertible notes with a face value of A$1 each to Mercer Street, with the convertible notes issued through a prospectus.

MGC Pharmaceuticals reveals strategic objectives for H1 2024

MGC Pharmaceuticals Ltd (LSE:MXC, OTC:MGCLF, ASX:MXC) CEO and Managing Director Roby Zomer speaks to Thomas Warner from Proactive London following the completion of a share consolidation and capital raise. With these restructuring initiatives completed, Zomer shares his enthusiasm for the...

on 11/13/2023